Kruppel-like factor (KLF) 6 is a tumor-suppressor gene functionally inactivated by loss of heterozygosity, somatic mutation and/or alternative splicing that generates a dominant-negative splice form, KLF6-SV1. Wild-type KLF6 (wtKLF6) expression is decreased in many human malignancies, which correlates with reduced patient survival. Additionally, loss of the KLF6 locus in the absence of somatic mutation in the remaining allele occurs in a number of human cancers, raising the possibility that haploinsufficiency of the KLF6 gene alone contributes to cellular growth dysregulation and tumorigenesis. Our earlier studies identified the cyclin-dependent kinase inhibitor p21 as a transcriptional target of the KLF6 gene in cultured cells, but not in vivo. To address this issue, we have generated two genetic mouse models to define the in vivo role of KLF6 in regulating cell proliferation and p21 expression. Transgenic overexpression of KLF6 in the liver resulted in a runted phenotype with decreased body and liver size, with evidence of decreased hepatocyte proliferation, increased p21 and reduced proliferating cell nuclear antigen expression. In contrast, mice with targeted deletion of one KLF6 allele (KLF6 þ /À) display increased liver mass with reduced p21 expression, compared to wild type littermates. Moreover, in primary hepatocellular carcinoma samples, there is a significant correlation between wtKLF6 and p21 mRNA expression. Combined, these data suggest that haploinsufficiency of the KLF6 gene may regulate cellular proliferation in vivo through decreased transcriptional activation of the cyclin-dependent kinase inhibitor p21.
Kruppel-like factor (KLF) 6 is a tumor-suppressor gene functionally inactivated by loss of heterozygosity, somatic mutation and/or alternative splicing that generates a dominant-negative splice form, KLF6-SV1. Wild-type KLF6 (wtKLF6) expression is decreased in many human malignancies, which correlates with reduced patient survival. Additionally, loss of the KLF6 locus in the absence of somatic mutation in the remaining allele occurs in a number of human cancers, raising the possibility that haploinsufficiency of the KLF6 gene alone contributes to cellular growth dysregulation and tumorigenesis. Our earlier studies identified the cyclin-dependent kinase inhibitor p21 as a transcriptional target of the KLF6 gene in cultured cells, but not in vivo. To address this issue, we have generated two genetic mouse models to define the in vivo role of KLF6 in regulating cell proliferation and p21 expression. Transgenic overexpression of KLF6 in the liver resulted in a runted phenotype with decreased body and liver size, with evidence of decreased hepatocyte proliferation, increased p21 and reduced proliferating cell nuclear antigen expression. In contrast, mice with targeted deletion of one KLF6 allele (KLF6 þ /À) display increased liver mass with reduced p21 expression, compared to wild type littermates. Moreover, in primary hepatocellular carcinoma samples, there is a significant correlation between wtKLF6 and p21 mRNA expression. Combined, these data suggest that haploinsufficiency of the KLF6 gene may regulate cellular proliferation in vivo through decreased transcriptional activation of the cyclin-dependent kinase inhibitor p21. Oncogene (2007) 26, 4428-4434; doi:10.1038/sj.onc.1210223; published online 5 February 2007 Keywords: KLF6; Kruppel-like factor; tumor-suppressor gene; p21; haploinsufficiency Kruppel-like factor 6 (KLF6) belongs to the Kruppellike family of transcription factors, which play roles in the regulation of diverse cellular processes including development, differentiation, proliferation and apoptosis (Bieker, 2001) . Functional inactivation of the KLF6 gene occurs through several mechanisms, including loss of heterozygosity (LOH), somatic mutation and/or increased alternative splicing that yields a dominantnegative splice isoform, KLF6-SV1. KLF6 dysregulation has been demonstrated in a number of human cancers including prostate (Narla et al., 2001; Chen et al., 2003) , colorectal , non-smallcell lung (Ito et al., 2004) , gastric (Cho et al., 2005) , nasopharyngeal (Chen et al., 2002) , hepatocellular (Kremer-Tal et al., 2004) and ovarian carcinomas (DiFeo et al., 2006b) as well as glioma (Jeng et al., 2003) . Furthermore, decreased KLF6 mRNA expression is associated with reduced patient survival in prostate (Singh et al., 2002; Glinsky et al., 2004) and lung cancers (Kettunen et al., 2004) . Interestingly, reconstitution of KLF6 decreases cell proliferation and reverts tumorigenicity in glioblastoma cell lines (Kimmelman et al., 2004) .
Depending on the cell type and context, KLF6's growth-suppressive properties have been associated with key pathways disrupted in human cancer, including p53-independent upregulation of p21 (Narla et al., 2001) , reduced interaction of cyclin D1 with CDK4 , induction of apoptosis (Ito et al., 2004) and inhibition of c-jun (Slavin et al., 2004) . Recently, a single nucleotide polymorphism in the KLF6 gene has been associated with increased prostate cancer risk (Narla et al., 2005) .
Overall, the majority of the published data to date report frequent LOH of the KLF6 gene locus in primary hepatocellular carcinoma (HCC) patient-derived samples. KLF6 LOH was reported in 36% of 14 informative HCC patient samples and somatic mutations were detected in three patient samples (Wang et al., 2004) . These findings complement our original report describing frequent loss and somatic mutation in primary HCC tumor samples (Kremer-Tal et al., 2004) . In a separate study, somatic mutations were identified in 8.7% of patient samples (Pan et al., 2006) . In addition, LOH was reported in 6.8% of tumors with no mutation or promoter methylation in a Korean cohort of HCCs (Song et al., 2006) . On the other hand, two reports have either failed to identify KLF6 mutations in HCC samples (Boyault et al., 2005) or did not find a decrease in KLF6 mRNA expression in HCCs (Wang et al., 2004) . However, methodologic differences may account for these discrepant results (Narla et al., 2003) . We and others have demonstrated significant downregulation of wtKLF6 expression by both quantitative real-time polymerase chain reaction (qRT-PCR) analysis and microarray studies in both HBV-and HCV-derived HCC patient samples (Lee et al., 2004; Kremer-Tal et al., 2006) . Although the frequency of somatic mutation in the KLF6 gene is quite variable, the bulk of evidence from published studies supports a role for the KLF6 tumor-suppressor gene in the development and progression of HCC, through either KLF6 loss and/ or somatic mutation and decreased wtKLF6 expression.
Interestingly, there are a number of tumor types in which loss of one KLF6 allele occurs in the absence of somatic mutation in the remaining allele, including glioblastoma, ovarian, gastric, and head and neck squamous cell cancers. This finding raises the possibility that haploinsufficiency of the KLF6 gene alone might contribute to increased cellular proliferation and tumor development in vivo. To explore this possibility, and to investigate the in vivo biologic activity of KLF6, we generated transgenic (TG) mice with hepatocyte-specific overexpression of KLF6 by using a well-validated TG construct (Wu et al., 1996) in which the human KLF6 cDNA was cloned downstream of the transthyretin (TTR) promoter. Three independent lines of mice, TTR1-KLF6, TTR4-KLF6 and TTR9-KLF6, were generated with modest (Btwo-to threefold) but reproducible expression of KLF6. Expression of the transgene is confined specifically to hepatocytes with variable expression in the choroid plexus of the brain at high transgene copy number (Wu et al., 1996) (data not shown). TG mice were analysed at 6 weeks of age as this is the period of rapid murine liver growth and differentiation (Walthall et al., 2005) , and studies of mice with hepatocyte specific overexpression of p21 (Wu et al., 1996) demonstrated a significant phenotype during this time period. Compared with wild-type (WT) littermates, KLF6 TG mice had diminished body weight and liver mass, with reduced serum albumin levels; serum-alanine aminotransferase (ALT) and -aspartate aminotransferase (AST) levels were normal, however, indicating a lack of hepatocyte injury, as documented also by lack of inflammatory infiltrates within the liver (Table 1) . Interestingly, the liver to total body ratio was not different between TG and WT mice suggesting that both are reduced equally in KLF6 TG mice. There was no distortion of liver architecture, although the length of hepatic plates was greatly reduced (Figure 1a and b) . This is nearly identical to the phenotype originally identified in mice in which hepatocyte-specific p21 expression was generated using the same promoter (Wu et al., 1996) . Expression of proliferating cell nuclear antigen (PCNA) in hepatocytes of 4-week-old TG pups was markedly diminished, consistent with reduced hepatocyte proliferation ( Figure  1c and d) . There was no increase in cellular apoptosis as assessed by TdT-mediated dUTP nick end labeling (TUNEL) (data not shown). Correlating with the decreased liver mass, TG mice yielded B50% fewer hepatocytes than their non-TG littermates, following cell isolation using standard methods -this difference was a result of decreased cellular proliferation, as assessed by 3 H thymidine incorporation and PCNA staining. No differences in apoptosis or cellular viability were noted between TG and WT-derived hepatocytes, as measured by TUNEL staining and fluorescence-activated cell sorting analysis. Of note, the altered weight, histology and KLF6 expression were confined only to the liver and there were no differences in these features in any other tissues.
Because an antiproliferative effect of KLF6 was apparent in the hepatocytes of TG mice, and as we had previously established that KLF6 transactivates p21 independent of p53 (Narla et al., 2001) , we examined the expression of p21, an inhibitor of several cyclindependent kinases and a key regulator of the G1/S transition (el-Deiry et al., 1993) . By Western blot, there was a threefold increase in KLF6 and a 10-fold increase in p21 in TG hepatocytes, which was associated with an B80% reduction in PCNA expression ( Figure 1e ) and a 50% reduction in DNA synthesis, as assessed by 3 H thymidine incorporation compared with hepatocytes isolated from WT mice (data not shown).
In light of the mounting number of studies reporting KLF6 involvement in HCC through LOH and/or mutation, and to further establish a direct relationship between KLF6 and p21 in vivo, we characterized the livers of KLF6 heterozygous (Het) mice that had been generated by homologous recombination and targeting of KLF6 exon 2, as described previously (Matsumoto et al., 2006) . Two independent lines of mice, AH2 and CH2, were generated and Het AH2 mice were examined. KLF6 Het mice were analysed between the ages of 50 and 70 weeks. This age was selected because previous studies describing haploinsufficiency of other tumorsuppressor genes, including p53, PTEN and SMAD4, (Figure 2a ). Hepatic KLF6 mRNA levels were reduced by 70% in KLF6 þ /À mice compared with WT littermates, which were associated with equal reductions in p21 mRNA, as assessed by qRT-PCR (Figure 2b ). These findings were further verified by semi quantitative RT-PCR, as illustrated in Figure 2c . In parallel with the mRNA expression levels from the KLF6 Het mice, both wtKLF6 and p21 protein levels were significantly reduced compared with WT littermates (Figure 2d and Supplementary Figure 2 ). Of note, there was no change in the hepatic expression of E-cadherin or inducible nitric oxide in the Het mice compared with WT littermates (See Supplementary Figure 1) , both of which (Bissell et al., 1980) were characterized from both TG and WT littermates. Western blotting was performed on cell extracts harvested from three KLF6 TG and WT mice in RIPA buffer (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Equal amounts of protein (50 mg; BioRad, Hercules, CA, USA; DC Protein quantification assay, BioRad) were loaded, separated by polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes and probed with anti-KLF6 (SC-7158), anti-p21 (SC-6246) (Santa Cruz Biotechnology) and anti-PCNA (DAKO, Catalog no. PM0879, Carpinteria, CA, USA) antibodies. KLF6 TG mice demonstrated a significant upregulation of the cyclin-dependent kinase inhibitor p21, with concomitant decreases in PCNA expression.
In vivo regulation of p21 by KLF6 G Narla et al . All values were calculated by normalizing the levels of each target for each cDNA to both GAPDH and b-actin to determine the relative amount of wtKLF6 in each sample. All experiments were performed in triplicate and repeated three independent times. In KLF6 Het mice, there was a B70% reduction in KLF6 and p21 mRNA levels compared with age-matched WT littermate liver samples (Po0.0001). (c) In order to confirm that the high cycle number obtained by qRT-PCR was a true representation of low mRNAs in the tissue and not a technical artifact owing to the formation of primer dimers, cDNAs from liver samples were also amplified by conventional PCR using GAPDH, wtKLF6 and p21 primers as indicated above. PCR reactions were performed for 25, 30, 35 and 40 cycles and the products were separated by agarose gel electropheresis. Although GAPDH expression was evident within the 25-30 cycles and equal between the WT and Het-derived liver RNA, wtKLF6 and p21 products were detected within the 35-40 cycles range in the livers of KLF6 Het mice, compared with the 30-35 cycles range for WT mice, indicating decreased wtKLF6 and p21 expression within the livers of KLF6 Het mice. (d) Mouse livers were homogenized using the T-PER buffer (Pierce, Rockford, IL, USA) and 0 mg of each of the lysates were separated by polyacrylamide gel electrophoresis. Gels were transferred to a nitrocellulose membrane that was blotted for KLF6 (1:250; Rabbit 1:2500; Santa Cruz SC-7158), p21 (SC-6246) and GAPDH (SC-32233). KLF6 Het mice had significantly reduced expression of KLF6 and p21 protein compared with WT littermates.
In vivo regulation of p21 by KLF6 G Narla et al have been previously shown to be regulated by KLF6 in other tissues or cell types (Warke et al., 2003; Difeo et al., 2006a) . Combined, these results suggest that KLF6 is a critical regulator of hepatocyte proliferation and liver size in vivo, at least in part through upregulation of the cyclin-dependent kinase inhibitor p21.
We have previously described decreased wtKLF6 mRNA expression in primary HCC samples compared with matched surrounding tissue (ST) (Kremer-Tal et al., 2006) . ST analysed here were either cirrhotic or non cirrhotic livers (Lee et al., 2004; see Supplementary Figure 4) . Based on our findings in the KLF6 mouse models, we examined the levels of KLF6 and p21 expression in a set of 33 HCC and matched ST (KremerTal et al., 2006) . RT-PCR using wtKLF6 and p21-specific primers demonstrated a significant correlation between decreased KLF6 and p21 mRNA expression in primary tumors compared with matched ST (P-value o0.05) (Figure 3 , Table 2 ), suggesting that decreased expression of p21 in primary tumors result in part from the downregulation of the KLF6 tumor-suppressor gene.
Previous reports in both ovarian and prostate cancer demonstrated that increased KLF6 alternative splicing into the dominant-negative isoform KLF6-SV1 results in functional inactivation of wtKLF6 tumor-suppressive function. Detailed analysis of KLF6 in the HCC samples demonstrated a relatively low prevalence of increased KLF6 splicing (See Supplementary Figure 3) . In addition, analysis of mouse tissue derived from both TG and WT mice revealed that although the KLF6 gene is alternatively spliced in the mouse, the dominantnegative KLF6-SV1 isoform is not expressed.
Our data reveal a unique role for KLF6 in regulating cell growth in vivo and suggest that upregulation of the cyclin-dependent kinase inhibitor p21 accounts for much of KLF6's growth-suppressive properties. In addition, loss of one KLF6 allele, a frequent event in human cancer, leads to decreased wtKLF6 and p21 expression in vivo suggesting that haploinsufficiency of the KLF6 gene may also contribute to tumorigenesis. Our results further establish p21 as a transcriptional target of KLF6. In addition to a direct antiproliferative effect mediated by p21, KLF6 may also indirectly inhibit cell growth through its ability to upregulate the antiproliferative cytokine transforming growth factor (TGF)b1 and its receptors (Kim et al., 1998) and to stimulate plasmin mediated activation of latent TGFb1 by driving transcription of the urokinase-type plasminogen activator gene (Botella et al., 2002) .
The decrease in hepatic synthetic function in KLF6 TG mice may reflect an indirect effect of impaired cellular growth, similar to that observed in TG mice with hepatocyte-specific expression of p21 (Wu et al., 1996) . Alternatively, KLF6 might directly impair hepatocyte differentiation through transactivation of target genes not yet identified. The current studies further enumerate the biologic pathways and mechanisms of KLF6 tumor suppressor gene and extend previous findings of KLF6 regulation of p21 to mouse models and human cancer in vivo. In addition, these current studies highlight the potential for haploinsufficiency of the KLF6 gene in the regulation of cellular proliferation in vivo. Combined, these findings highlight not only the general role of KLF6 in cancer pathogenesis, but also the mechanisms of its action and regulation on key pathways regulating cell proliferation in vivo. Abbreviations: HCC, hepatocellular carcinoma; KLF6, Kruppel-like factor 6; ST, surrounding tissue. mRNA levels for both KLF6 and p21 in HCC patient samples were categorized as either higher or lower than their matched ST. There was a significant correlation between tumors expressing low levels of p21 and wtKLF6 mRNAs (Po0.05).
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